StockData
Rallybio Corp logo

Rallybio Corp (RLYB) stock

RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)

Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –

Rallybio cash

Cash and short-term investments held at the end of each period.

Rallybio's cash was $90.70M at Sep 30, 2026. For fiscal 2025 it was $54.70M, down 16.5% from the year before. The highest annual figure on record is $175.33M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$54.70M-16.5%
FY2024Dec 31, 2024$65.50M-40.4%
FY2023Dec 31, 2023$109.90M-35.0%
FY2022Dec 31, 2022$169.00M-3.6%
FY2021Dec 31, 2021$175.33M+25.0%
FY2020Dec 31, 2020$140.23M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$90.70M+53.0%
Q2 FY2026Jun 30, 2026$92.80M+103.1%
Q1 FY2026Mar 31, 2026$46.80M-14.1%
Q4 FY2025Dec 31, 2025$54.70M-16.5%
Q3 FY2025Sep 30, 2025$59.30M-21.0%
Q2 FY2025Jun 30, 2025$45.70M-48.4%
Q1 FY2025Mar 31, 2025$54.50M-42.1%
Q4 FY2024Dec 31, 2024$65.50M-40.4%
Q3 FY2024Sep 30, 2024$75.10M-38.1%
Q2 FY2024Jun 30, 2024$88.60M-35.7%
Q1 FY2024Mar 31, 2024$94.20M-37.4%
Q4 FY2023Dec 31, 2023$109.90M-35.0%
Q3 FY2023Sep 30, 2023$121.40M-8.3%
Q2 FY2023Jun 30, 2023$137.80M-6.5%
Q1 FY2023Mar 31, 2023$150.40M-6.8%
Q4 FY2022Dec 31, 2022$169.00M-3.6%
Q3 FY2022Sep 30, 2022$132.40M-29.2%
Q2 FY2022Jun 30, 2022$147.40M+30.8%
Q1 FY2022Mar 31, 2022$161.40M+15.1%
Q4 FY2021Dec 31, 2021$175.33M–
Q3 FY2021Sep 30, 2021$186.98M–
Q2 FY2021Jun 30, 2021$112.73M–
Q4 FY2020Dec 31, 2020$140.23M–

More Rallybio figures

See a number that looks wrong?